Literature DB >> 17387038

Evaluation of chemopreventive agents for genotoxic activity.

Rupa S Doppalapudi1, Edward S Riccio, Linda L Rausch, Julie A Shimon, Pam S Lee, Kristien E Mortelmans, Izet M Kapetanovic, James A Crowell, Jon C Mirsalis.   

Abstract

We conducted genetic toxicity evaluations of 11 candidate chemopreventive agents with the potential for inhibiting carcinogenesis in humans at increased risk of cancer. The compounds were evaluated for bacterial mutagenesis in the Salmonella-E. coli assay, for mammalian mutagenesis in mouse lymphoma cells, for chromosome aberrations in Chinese Hamster Ovary (CHO) cells, and for micronucleus induction in mouse bone marrow. Tested agents were indole 3-carbinol (I3C), bowman-birk inhibitor concentrate (BBIC), black tea polyphenols (BTP), farnesol, geraniol, l-Se-methylselenocysteine (SeMC), 5,6-dihydro-4H-cyclopenta[1,2]-dithiol-3-thione(DC-D3T), 4'-bromoflavone, 2,5,7,8-tetramethyl-(2R-[4R,8R,12-trimethyltridecyl] chroman-6-yloxy) acetic acid (alpha-TEA), SR13668 (2,10-dicarbethoxy-6-methoxy-5,7-dihydro-indolo[2,3-b] carbazole and SR16157 (3-O-sulfamoyloxy-7alpha-methyl-21-(2-N,N-diethylaminoethoxy)-19-norpregna-1,3,5(10)-triene). All these agents, except I3C and BTP, were negative in the Salmonella-E. coli assay in the presence and absence of metabolic activation (S9). I3C and BTP induced a weak mutagenic response in the presence and absence of S9 with strains TA100 and TA98, respectively. Of the three compounds tested in the mouse lymphoma assay (I3C, BBIC, and BTP), only BTP was mutagenic in the presence of S9. In the chromosomal aberration assay, of the 8 compounds that were tested, 4'-bromoflavone elicited a positive response in the absence of S9 only, while SR16157 was positive in the presence of S9. The results with geraniol remain inconclusive. I3C, BBIC and BTP were not tested in the chromosomal aberration assay. None of the 11 agents induced micronuclei in mouse bone marrow erythrocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387038     DOI: 10.1016/j.mrgentox.2007.02.004

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

Review 1.  Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics.

Authors:  Fazlul H Sarkar; Yiwei Li
Journal:  Cancer Treat Rev       Date:  2009-08-05       Impact factor: 12.111

2.  Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.

Authors:  Joel M Reid; Chad A Walden; Rui Qin; Katie L Allen Ziegler; John L Haslam; Roger A Rajewski; Roger Warndahl; Cindy L Fitting; Daniel Boring; Eva Szabo; James Crowell; Marjorie Perloff; Ling Jong; Brent A Bauer; Sumithra J Mandrekar; Matthew M Ames; Paul J Limburg
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

3.  Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent.

Authors:  Carol E Green; Robert Swezey; James Bakke; Walter Shinn; Anna Furimsky; Naveen Bejugam; Gita N Shankar; Ling Jong; Izet M Kapetanovic
Journal:  Cancer Chemother Pharmacol       Date:  2010-07-10       Impact factor: 3.333

4.  Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen.

Authors:  Rupa S Doppalapudi; Edward S Riccio; Zoe Davis; Sean Menda; Abraham Wang; Nicholas Du; Carol Green; Levy Kopelovich; Chinthalapally V Rao; Doris M Benbrook; Izet M Kapetanovic
Journal:  Mutat Res       Date:  2012-04-10       Impact factor: 2.433

5.  Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.

Authors:  Sidharth Chopra; Gary A Koolpe; Arlyn A Tambo-Ong; Karen N Matsuyama; Kenneth J Ryan; Tran B Tran; Rupa S Doppalapudi; Edward S Riccio; Lalitha V Iyer; Carol E Green; Baojie Wan; Scott G Franzblau; Peter B Madrid
Journal:  J Med Chem       Date:  2012-06-25       Impact factor: 7.446

6.  Rapid access to preventive intervention development program in the Division of Cancer Prevention of the U.S. National Cancer Institute: an overview.

Authors:  Izet M Kapetanovic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-24       Impact factor: 4.254

7.  Preclinical studies on the pharmacokinetics, safety, and toxicology of oxfendazole: toward first in human studies.

Authors:  Ellen E Codd; Hanna H Ng; Claire McFarlane; Edward S Riccio; Rupa Doppalapudi; Jon C Mirsalis; R John Horton; Armando E Gonzalez; H Hugo Garcia; Robert H Gilman
Journal:  Int J Toxicol       Date:  2015-02-20       Impact factor: 2.032

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.